RecruitingNot ApplicableNCT06583811

Remifentanil and Remimazolam to Limit Patient Movement

Remifentanil and Remimazolam to Limit Patient Movement During Long-Eye Surgeries Under Local Anesthesia


Sponsor

Egymedicalpedia

Enrollment

70 participants

Start Date

Jul 10, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Local anesthetics (LA) may be administered by injection (retrobulbar, peribulbar, subconjunctival, lid, or facial block) or by instillation (topical anesthesia), Considerable drawbacks of local anesthesia in these patients include the fact that a few patients can remain comfortable on an operating table for procedures that exceed two or three hours. Sedation may be helpful with LA to decrease the experience of discomfort, movement and anxiety, which may in turn positively influence hemodynamic parameters, patient satisfaction, and overall improve surgical safety. Sedatives used in eye surgeries include benzodiazepines, opioids, alpha-adrenoceptor agonists, and propofol.


Eligibility

Min Age: 40 YearsMax Age: 50 Years

Inclusion Criteria4

  • Age > 40 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status I-III.
  • Undergoing long-eye surgeries under local anesthesia using peribulbar block with an expected surgical time of more than one hour.

Exclusion Criteria10

  • Patients on aspirin or anticoagulants.
  • Allergy to any study medication.
  • Drug abuse.
  • Uncontrolled hypertension.
  • Hyperthyroidism.
  • Frequent cough.
  • Impaired hearing.
  • Severe liver and kidney dysfunction.
  • Neurological or psychological disorders.
  • Partial or failed block.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRemifentanil

to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.


Locations(1)

Al-Azhar University hospitals

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06583811